## Supplementary file 1: PRISMA-P checklist

Section and topic	Item	Checklist Item	Reported on	
	No.		page #	
A) Administrative	Inform	ation	1. 0	
Identification	1a	Identify the report as a protocol of a systematic review	1	
Update	1b	Identify protocol as an update of a previous systematic	n/a	
		review if applicable		
Registration	2	Name of registry and registration number	2	
B) Authors	I	1	•	
Contact		Provide name, institutional affiliation, e-mail address	1	
		of all protocol authors; provide physical mailing		
		address of corresponding author		
Contributions		Describe contributions of protocol authors and identify	1+12	
		the guarantor of the review		
Amendments		If the protocol represents an amendment of a	n/a	
		previously completed or published protocol, identify as		
		such and list changes; otherwise, state plan for		
		documenting important protocol amendments		
Support				
- Sources	5a	Indicate Sources of financial or other support for the	12	
		review		
- Sponsor	5b	Provide name for the review funder and/or sponsor	11	
- Role of	5c	Describe roles of funder(s), sponsor(s) and/or	13	
sponsor or		institution(s), if any, in developing the protocol		
funder				
C) Introduction	I			
Rationale	6	Describe the rationale for the review in the context of	3 + 4	
		what is already known		
Objectives	7	Provide an explicit statement of the question(s) the	4 + 5	
		review will address with reference to participants,		
		interventions, comparators, and outcomes (PICO)		
D) Methods			I.	
Eligibility Criteria	8	Specify the study characteristics (such as PICO, study	5+6+7	
		design, setting, time frame) and report characteristics		
		(such as years considered, language, publication		
		status) to be used as criteria for eligibility for the		
		review		
Information Sources	9	Describe all intended information sources (such as	7+8	
		electronic databases, contact with study authors, trial		
		registers or other grey literature sources) with planned		
		dates of coverage		
Search Strategy	10	Present draft of search strategy to be used for at least	Supplementary	
<i>3,</i>		one electronic database, including planned limits, such	file 2	
		that it could be repeated		
E) Study Records				
Data Management	11a	Describe the mechanism(s) that will be used to	8	
		manage records and data throughout the review		
			l	

Selection Process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	5 - 10
Data Collection	11c	Describe planned method of extracting data from	8 - 10 +
Process		reports (such as piloting forms, done independently, in	Supplementary
		duplicate), any processes for obtaining and confirming data from investigators	file3
Data Items	12	List and define all variables for which data will be	8 - 9
		sought (such as PICO items, funding sources), any pre-	
		planned data assumptions and simplifications	
Outcomes and	13	List and define all outcomes for which data will be	6 + 9
prioritization		sought, including prioritization of main and additional	
		outcomes, with rationale	
Section and topic	Item	Checklist Item	Reported on
	No.		page #
Risk of bias in	14	Describe anticipated methods for assessing risk of bias	9
individual studies		of individual studies, including whether this will be	
		done at the outcome or study level, or both; state how	
		this information will be used in data synthesis	
Data Synthesis	15a	Describe criteria under which study data will be	9 + 10
		quantitatively synthesised	
	15b	If data are appropriate for quantitative synthesis,	10
		describe planned summary measures, methods of	
		handling data and methods of combining data from	
		studies, including any planned exploration of	
		consistency	
	15c	Describe any proposed additional analyses (such as	10
	45 :	sensitivity or subgroup analyses, meta-regression)	0 10
	15d	If quantitative synthesis is not appropriate, describe	9 – 10
	16	the type of summary planned	
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such	n.a.
		as publication bias across studies, selective reporting	
Can Calana :	1-	within studies)	0 10
Confidence in	17	Describe how the strength of the body of evidence will	9 – 10
cumulative evidence		be assessed	